Earlier this week, Sanofi filed suit against Mylan, alleging it had been operating illegally by attempting to squelch competition to EpiPen. The lawsuit was filed in federal court in Trenton, New Jersey.
According to Sanofi, what Mylan has done has resulted in Sanofi losing hundreds of millions of dollars in rival Auvi-Q sales.
Mylan executives had previously offered price rebates to persuade government officials, insurance companies and pharmaceutical benefit managers not to reimburse patients for Auvi-Q. Sanofi alleges that Mylan also had been requiring schools to agree to use EpiPen exclusively for discounts.
Read the Bloomberg report